SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the first quarter ended March 31, 2017.
“We continue to make important progress advancing our lead product candidate, GBT440, across both our sickle cell disease (SCD) and idiopathic pulmonary fibrosis (IPF) indications,” said Ted W. Love, M.D., president and chief executive officer of GBT. “We are focused on activating new clinical trial sites for our pivotal HOPE Study to support ongoing enrollment and look forward to highlighting preliminary results from our Phase 2a study of GBT440 in adolescents, 12-17 years old, at the Congress of the European Hematology Association (EHA). Additionally, we remain on track to report data from our ongoing studies supporting our hypoxemia program later this year.”
